Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential

6. Pfizer Inc. (NYSE:PFE)

Upside Potential: 37.43%

Number of Hedge Fund Holders: 92

Founded in 1849 and based in New York City, Pfizer Inc. (NYSE:PFE) is a leading pharmaceutical company with a diverse portfolio that includes rare illnesses, cancer, inflammation, and vaccines. The company’s RSV vaccine, ABRYSVO, is a major factor in its future growth as it keeps growing its presence in the adult and maternal vaccination markets.

Pfizer Inc. (NYSE:PFE) made $63.6 billion in 2024, thanks to robust sales of its non-COVID drugs, which saw an operational growth of 12%. The company paid out $9.5 billion in dividends to stockholders and recorded adjusted earnings per share of $3.11, up from $1.84 in 2023. In addition, Pfizer reduced its debt by $7.8 billion and made roughly $11 billion in internal research and development.

Looking ahead, Pfizer Inc. (NYSE:PFE) projects $61–$64 billion in revenue and $2.80–$3.00 in earnings per share for 2025. The company’s priorities include increasing R&D productivity, starting up to 13 pivotal trials, and advancing important medications, including sigvotatug vedotin (ADC), atirmociclib (a CDK4 inhibitor), and vaccinations like PCV-25 and C. diff. Furthermore, Pfizer is confident in its cost-saving plan, which aims to recover to pre-COVID operating margins and save $4.5 billion by the end of 2025, despite challenges from Medicare reforms under the IRA.

Adults aged 50–59 who are at a higher risk of developing severe RSV-associated lower respiratory tract disease (LRTD) should also receive the RSV vaccination, according to a vote made by the CDC’s Advisory Committee on Immunization Practices (ACIP) in April 2025. Among them is ABRYSVO, which the FDA authorized in October 2024 for use in high-risk people between the ages of 18 and 59. The change greatly expands the vaccine’s eligible population, subject to final approval. The European Commission recently amended the vaccine’s authorization to cover a larger adult population in March 2025, and it is currently approved in a number of overseas markets.

Thus, as Pfizer Inc. (NYSE:PFE) negotiates the post-COVID environment, ABRYSVO is becoming a key component of its vaccination approach. A restoration to revenue momentum is shown by the company’s wider RSV coverage, which also helps its competitive positioning.

Pfizer continues to be a carefully watched healthcare stock with promising long-term catalysts, thanks to significant institutional support, including a position in Ken Fisher’s stock portfolio.